Perioperative functional activity of the alternative pathway of complement in patients with colonic cancer

European Journal of Surgery

Volumn 165, Issue 10, 1999, Pages 962-965

  Baatrup, Gunnar ^a   Zimmermann Nielsen, Erik ^a   Qvist, Niels ^b  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Alternative pathway of complement; Colon cancer; ELISA; Preoperative measurement

Indexed keywords

COMPLEMENT COMPONENT C3B;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COLON CANCER; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; FEMALE; HUMAN; HUMORAL IMMUNITY; MALE; MEASUREMENT; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; COLONIC NEOPLASMS; COMPLEMENT C3B; COMPLEMENT FIXATION TESTS; COMPLEMENT PATHWAY, ALTERNATIVE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; MONITORING, INTRAOPERATIVE; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; REFERENCE VALUES;

EID: 0032744453     PISSN: 11024151     EISSN: None     Source Type: Journal    
DOI: 10.1080/110241599750008080     Document Type: Article

References (11)

1. Baatrup G, Qvist N, Junker A, Larsen K-E, Zimmermann-Nielsen C. Activity and activation of the complement system in patients being operated on for cancer of the colon. Eur J Surg 1994; 160: 503-510.
2. Baatrup G, Jonsson H, Sjöholm A, Sturfelt G, Svehag SE. Complement fixation by solid phase immune complexes. Reduced capacity in SLE sera. J Clin Lab Immunol 1988; 26: 73-79.
3. Baatrup G, Svehag S-E, Jensenius JC. The attachment of serum and plasma derived C3 to solid phase immune aggragates and its relation to complement mediated solubilization of immune complexes. Scand J Immunol 1986; 23: 397-406.
4. Gardiner JS, Keil LD, DeBari VA. In vitro formation of complement activation products by lipopolysaccaride chemotypes of Salmonella Minnesota. Int Arch Allergy Appl Immunol 1991; 96: 51-54.
5. Guidi L, Baroni R, Bartoloni C, et al. Immune complexes in solid tumors precipitable by 3.5% polyethylene glycol: analysis of some nonspecific factors. Diagnostic and Clinical Immunol 1988; 5: 284-288.
6. Lehto T, Meri S. Interactions of soluble CD59 with the terminal complement complexes. J Immunol 1993; 151: 4941-4949.
7. Marquart HV, Svehag S-E, Leslie GQ. CR2 is the primary acceptor site for C3 during alternative pathway activation of complement on human peripheral B lymphocytes. J Immunol 1994; 153: 307-315.
8. Paugburn MK, Morrison DC, Schreiber RD, Müller-Eberhard HJ. Activation of the alternative complement pathway: recognition of surface structures on activators by bound C3b. J Immunol 1980; 124: 977-982.
9. Reiter V, Fishelson Z. Targeting of complement to tumor cells by heteroconjungates composed of antibodies and of complement component C3b. J Immunol 1989; 142: 2771-2777.
10. Schieren G, Hänsch GM. Membrane associated proteins regulating the complement system: Functions and deficiencies. Intern Rev Immunol 1993; 10: 87-101.
11. Väkevä A, Laurila P, Meri S. Regulation of complement membrane attack complex formation in myocardial infarction. Am J Pathol 1993; 143: 65-75.